These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10809747)

  • 21. Complex formation between the hepatitis C virus serine protease and a synthetic NS4A cofactor peptide.
    Bianchi E; Urbani A; Biasiol G; Brunetti M; Pessi A; De Francesco R; Steinkühler C
    Biochemistry; 1997 Jun; 36(25):7890-7. PubMed ID: 9201934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C NS3 protease: restoration of NS4A cofactor activity by N-biotinylation of mutated NS4A using synthetic peptides.
    Butkiewicz NJ; Yao N; Wright-Minogue J; Zhang R; Ramanathan L; Lau JY; Hong Z; Dasmahapatra B
    Biochem Biophys Res Commun; 2000 Jan; 267(1):278-82. PubMed ID: 10623610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.
    Barbato G; Cicero DO; Cordier F; Narjes F; Gerlach B; Sambucini S; Grzesiek S; Matassa VG; De Francesco R; Bazzo R
    EMBO J; 2000 Mar; 19(6):1195-206. PubMed ID: 10716920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease.
    Narjes F; Brunetti M; Colarusso S; Gerlach B; Koch U; Biasiol G; Fattori D; De Francesco R; Matassa VG; Steinkühler C
    Biochemistry; 2000 Feb; 39(7):1849-61. PubMed ID: 10677236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies.
    Cicero DO; Barbato G; Koch U; Ingallinella P; Bianchi E; Nardi MC; Steinkühler C; Cortese R; Matassa V; De Francesco R; Pessi A; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):385-96. PubMed ID: 10366512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.
    Dimasi N; Pasquo A; Martin F; Di Marco S; Steinkühler C; Cortese R; Sollazzo M
    Protein Eng; 1998 Dec; 11(12):1257-65. PubMed ID: 9930676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
    Dimasi N; Martin F; Volpari C; Brunetti M; Biasiol G; Altamura S; Cortese R; De Francesco R; Steinkühler C; Sollazzo M
    J Virol; 1997 Oct; 71(10):7461-9. PubMed ID: 9311825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic and structural analyses of hepatitis C virus polyprotein processing.
    Bartenschlager R; Ahlborn-Laake L; Mous J; Jacobsen H
    J Virol; 1994 Aug; 68(8):5045-55. PubMed ID: 8035505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RNA aptamer-binding site of hepatitis C virus NS3 protease.
    Hwang J; Fauzi H; Fukuda K; Sekiya S; Kakiuchi N; Shimotohno K; Taira K; Kusakabe I; Nishikawa S
    Biochem Biophys Res Commun; 2000 Dec; 279(2):557-62. PubMed ID: 11118325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis.
    Sardana VV; Blue JT; Zugay-Murphy J; Sardana MK; Kuo LC
    Protein Expr Purif; 1999 Aug; 16(3):440-7. PubMed ID: 10425166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.
    Butkiewicz NJ; Wendel M; Zhang R; Jubin R; Pichardo J; Smith EB; Hart AM; Ingram R; Durkin J; Mui PW; Murray MG; Ramanathan L; Dasmahapatra B
    Virology; 1996 Nov; 225(2):328-38. PubMed ID: 8918919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase.
    Bartenschlager R; Ahlborn-Laake L; Yasargil K; Mous J; Jacobsen H
    J Virol; 1995 Jan; 69(1):198-205. PubMed ID: 7983710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of the protease domain in NS3 of hepatitis C virus.
    Han DS; Hahm B; Rho HM; Jang SK
    J Gen Virol; 1995 Apr; 76 ( Pt 4)():985-93. PubMed ID: 9049347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substrate specificity of the NS3 serine proteinase of hepatitis C virus as determined by mutagenesis at the NS3/NS4A junction.
    Leinbach SS; Bhat RA; Xia SM; Hum WT; Stauffer B; Davis AR; Hung PP; Mizutani S
    Virology; 1994 Oct; 204(1):163-9. PubMed ID: 8091650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A scintillation proximity active site binding assay for the hepatitis C virus serine protease.
    Steinkühler C; Biasiol G; Cerretani M; Di Renzo L; Brunetti M; Ingallinella P; De Francesco R; Altamura S
    Anal Biochem; 2002 Aug; 307(1):99-104. PubMed ID: 12137785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions.
    Tautz N; Kaiser A; Thiel HJ
    Virology; 2000 Aug; 273(2):351-63. PubMed ID: 10915606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics.
    Lin C; Prágai BM; Grakoui A; Xu J; Rice CM
    J Virol; 1994 Dec; 68(12):8147-57. PubMed ID: 7966606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism.
    Barbato G; Cicero DO; Nardi MC; Steinkühler C; Cortese R; De Francesco R; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):371-84. PubMed ID: 10366511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and docking studies of peptide inhibitors as potential antiviral drugs for dengue virus ns2b/ns3 protease.
    Velmurugan D; Mythily U; Rao K
    Protein Pept Lett; 2014; 21(8):815-27. PubMed ID: 23855663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor.
    Brinkworth RI; Fairlie DP; Leung D; Young PR
    J Gen Virol; 1999 May; 80 ( Pt 5)():1167-1177. PubMed ID: 10355763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.